# Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
Canonical URL: https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-announces-new-research-supporting-integration-and-use-of-pedmarkr-at-the-2026-asco-annual-meeting
Ticker: FENC
Company: Fennec Pharmaceuticals Inc.
Source: Fennec Pharmaceuticals Inc.
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.fennecpharma.com
## Summary

~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ ~ Real-World Evidence Shows Administration of PEDMARK ® Approximately Six Hours After Cisplatin Can Be Safe & Easily

## Article Body
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ ~ Real-World Evidence Shows Administration of PEDMARK ® Approximately Six Hours After Cisplatin Can Be Safe & Easily
## Recent Company News
- 2026-06-25 13:46 EST — [Fennec Announces Results of Annual Meeting](https://biopharmsignal.com/news/FENC/fennec-announces-results-of-annual-meeting) — Source: Fennec Pharmaceuticals Inc.
- 2026-06-25 13:46 EST — [Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-announces-new-research-supporting-integration-and-use-of-pedmarkr-at-the-2026-asco-annual-meeting) — Source: Fennec Pharmaceuticals Inc.
- 2026-06-25 13:46 EST — [Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Fennec Pharmaceuticals Inc.
- 2026-06-25 13:46 EST — [Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Fennec Pharmaceuticals Inc.
- 2026-06-25 13:46 EST — [Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026](https://biopharmsignal.com/news/FENC/fennec-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-may-14-2026) — Source: Fennec Pharmaceuticals Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)